Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T).
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Reinhard Dummer, Daniel Gusenleitner, Catarina D. Campbell, Celeste Lebbe, Victoria Atkinson, Mario Mandalà, Paul D. Nathan, Ana Arance, Erika Richtig, Naoya Yamazaki, Caroline Robert, Dirk Schadendorf, Hussein Abdul-Hassan Tawbi, Paolo Antonio Ascierto, Antoni Ribas, Keith Flaherty, Eduard Gasal, Jan C. Brase, Georgina V. Long
Institutions: University Hospital Zurich, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, HIPI - Immunologie humaine, physiopathologie et immunithérapie, The University of Queensland, Greenslopes Private Hospital, Gallipoli Medical Research Foundation, Ospedale Papa Giovanni XXIII, Mount Vernon Cancer Centre, Hospital Clínic de Barcelona, Medical University of Graz, National Cancer Center Hospital, Institut Gustave Roussy, Essen University Hospital, Deutsches Konsortium für Translationale Krebsforschung, The University of Texas MD Anderson Cancer Center, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", University of California, Los Angeles, Harvard University, Massachusetts General Hospital, Dana-Farber Cancer Institute, Novartis (Switzerland), The University of Sydney, Melanoma Institute Australia
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
Funder: Novartis
OpenAlex ID: W4238464470